Steovit D3 is applied across domains where additional symptomatic support is needed. This medication is commonly used to help with the treatment and prevention of defined states of calcium deficiency and vitamin D deficiency, and as adjunct therapy for osteoporosis. These conditions can create noticeable physiological strain, making supportive management relevant when symptoms interfere with daily functioning.

“It is commonly used to help with symptoms that create noticeable physiological strain, helping to maintain a sense of stability during symptomatic phases.”

The treatment supports general well-being in adults, particularly for the elderly and postmenopausal women, by contributing to improved bone mineralization. This may assist with maintaining functional stability and supports the patient during difficult episodes by easing the symptom burden associated with the risk of fracture.

Quick Fact: Relief for Deficiency Symptoms
Main Use: Addresses calcium and vitamin D deficiency in contexts where additional symptomatic support is needed.
Primary Benefit: Contributes to easing the overall symptom load related to skeletal fragility.

Who can and cannot use Steovit D3?

The official eligibility for Steovit D3, a calcium and Vitamin D combination, is strictly defined by regulatory documents, focusing on patient age, organ function, and specific pre-existing conditions.

Eligibility Scope	Official Regulatory Status
Populations for whom use is allowed	Adults and the Elderly are the principal approved populations. Adolescents (typically 12 years and over) are permitted for treating or preventing deficiency.
Populations for whom use is contraindicated	The medicine must not be used in patients with hypercalcaemia (high blood calcium), hypercalciuria (high urine calcium), hypervitaminosis D, nephrolithiasis (kidney stones), or severe renal impairment.
Age-related eligibility rules	Use is not recommended for children under 12 years of age, often due to a lack of specific data or the unsuitability of the adult dosage strength.
Pregnancy and lactation eligibility	Pregnancy and Lactation represent a restricted status. High-dose use is generally not recommended, and any use requires close medical supervision to prevent hypercalcaemia, which could pose a risk to the fetus or infant.

Eligibility-related restrictions: Use requires caution and monitoring of calcium levels in patients with sarcoidosis, long-term immobilization, or any pre-existing impaired kidney function, as these conditions increase the risk of hypercalcaemia.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Steovit D3 (Calcium Carbonate and Dihydrotachysterol) as described in regulatory documents.

---

Documented Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type	Interacting Medicines and Substances
Additive Calcaemic Effect	Thiazide Diuretics (e.g., Hydrochlorothiazide) are documented to enhance the calcaemic response, increasing the risk of hypercalcaemia.
Enhanced Toxicity Risk	Cardiac Glycosides (e.g., Digoxin): Hypercalcaemia resulting from Steovit D3 may potentiate the toxic effects of these medicines.
Reduced Exposure/Efficacy	Anticonvulsants (e.g., Phenytoin) and Rifampicin may reduce the effectiveness of the Vitamin D component by increasing its metabolic clearance. Bile Acid Sequestrants (e.g., Cholestyramine) and Systemic Corticosteroids may impair absorption.

---

Mandatory Administration Constraints

The regulatory profile establishes specific timing and co-administration restrictions to manage potential interference:

• Contraindicated Combinations: Co-administration with other Vitamin D Analogs and high-dose Calcium Supplements is prohibited due to the risk of additive hypercalcaemia.
• Timing Separation: Tetracycline Preparations must be administered at least two hours before or four to six hours after Steovit D3 intake. Bisphosphonates and Sodium Fluoride require administration at least three hours before the calcium/vitamin D combination.
• Dietary Note: Ingestion of Steovit D3 is restricted within two hours of consuming foods high in oxalic or phytic acid.

Population Considerations

Patients with impaired renal function are noted to be more susceptible to hypercalcaemia and toxic effects from Vitamin D analog interactions, necessitating caution.

VDR Agonism and Calcium Homeostasis

Steovit D3 functions via two synergistic mechanisms: hormonal signaling and direct substrate supply. The cholecalciferol (Vitamin D3) component is metabolized to its active form, calcitriol, which acts as an agonist on the Vitamin D Receptor (VDR) in intestinal and kidney cells. This interaction is a genomic mechanism that transcriptionally increases the synthesis of proteins required to elevate the capacity for intestinal absorption of calcium ( Ca^2+) and phosphate from the digestive tract into circulation. The regulated increase in circulating Ca^2+ levels provides negative feedback to the parathyroid gland, which suppresses Parathyroid Hormone (PTH) secretion, thereby stabilizing mineral balance and reducing the physiological drive to mobilize calcium from the skeleton. The calcium carbonate component acts as the direct essential substrate for skeletal mineralization, contributing to a net positive bone mineral balance through the deposition of Ca^2+ into the organic bone matrix.

How Steovit D3 is Used: Official Administration Guidelines

Steovit D3 is a fixed-dose combination product containing calcium carbonate and cholecalciferol (Vitamin D3), and its administration follows specific standardized rules.

---

Administration Scope

The approved route of administration for all formulations is oral use. The standard dosing schedule for adults and the elderly typically involves one tablet once daily for higher strength variants (e.g., 1000 mg Calcium/800 IU D3), or up to three times daily for lower strength products, determined by individual patient needs.

Instruction	Detail
Preparation Requirements	Chewable tablets must be chewed or sucked and not swallowed whole. Effervescent tablets must be dissolved completely in water before being consumed.
Timing in Relation to Meals	Steovit D3 may generally be taken at any time, with or without food.
Age-Group Rules	No dosage adjustment is required for patients with hepatic impairment. Use is not recommended in patients with severe renal impairment (GFR less than 30 mL/min/1.73 m^2).

---

Special Procedural Conditions

This medication is intended for prolonged use as part of a long-term nutritional strategy. A crucial procedural condition is the requirement for separated administration from certain other oral medications, such as tetracycline antibiotics or bisphosphonates. To ensure proper absorption of both agents, a time gap of two to six hours must separate the intake of Steovit D3 from these concomitant drugs.

This procedural structure ensures consistent, standardized administration throughout the required treatment duration.

Recent Clinical Evidence Overview

Clinical studies concerning fixed-dose combinations of calcium carbonate and cholecalciferol (Vitamin D3), such as Steovit D3, primarily focus on their role as a supplement to other osteoporosis treatments or for addressing deficiencies. The established use is as an adjunct to specific osteoporosis therapy in patients at risk of calcium and vitamin D deficiency, or for the prevention and treatment of these deficiencies in the elderly.

---

Efficacy Findings

Evidence from meta-analyses of randomized controlled trials (RCTs) has explored the effect of combined calcium and Vitamin D supplementation on bone health outcomes, particularly in older adults:

• Fracture Risk: Several large-scale analyses suggest that the combination of calcium and Vitamin D supplementation is associated with a reduction in the risk of total fractures and hip fractures, particularly in institutionalized or older adults with demonstrated deficiency. However, results across studies in community-dwelling populations have been mixed.
• Bone Mineral Density (BMD): Supplementation may support the maintenance of Bone Mineral Density (BMD), especially when baseline Vitamin D levels are low. The effect on BMD tends to plateau after approximately one year of use.

---

Safety Considerations

Monitoring of adverse events in clinical settings focuses primarily on potential imbalances related to mineral metabolism:

• Hypercalcemia: Careful monitoring of serum calcium levels is necessary, especially during prolonged treatment or in patients receiving high doses of Vitamin D, as hypercalcemia (abnormally high calcium levels) is a known potential event.
• Renal Function: Studies emphasize the importance of monitoring renal function (via serum creatinine) in patients on long-term treatment, particularly for those with pre-existing kidney impairment, due to the risk of calcification or kidney stone formation.

Key Studies & References

1. Risk of hypercalcemia with calcium and vitamin D supplementation: systematic review and meta-analysis of randomized controlled trials

Common questions about Steovit D3 (FAQ)

---

Q: What is the main difference between Steovit D3 and just taking a regular calcium supplement?

A: Steovit D3 is officially described as a fixed-dose combination product. This means it contains the mineral calcium carbonate alongside Dihydrotachysterol, a synthetic regulator that acts like a Vitamin D analog. Taking a regular calcium supplement alone would not provide this co-formulated Vitamin D component.

Q: Is Steovit D3 generally used to prevent or to treat a condition?

A: Official regulatory documents describe its uses in both ways. It is used as an adjunct (or supportive treatment) to specific therapy for osteoporosis. It is also used for the prevention and treatment of established calcium and vitamin D deficiencies.

Q: What is the general difference between Steovit D3 and the Steovit-only product?

A: Steovit D3 is formally defined as a fixed-dose combination containing both calcium carbonate and a Vitamin D analog. The name suggests that a Steovit-only product would be a preparation focused on providing only the calcium component.

Q: Can Steovit D3 affect the results of general blood tests?

A: Regulatory information indicates that the medicine has an effect on the body’s mineral balance. For this reason, official documents emphasize the need for regular monitoring of serum calcium and renal function (via serum creatinine) during use. These monitoring requirements indicate that blood test results are a key part of the assessment process.

Q: Is it safe to take Steovit D3 for a long period of time, like several years?

A: Regulatory documents indicate the product is used in the context of long-term nutritional strategies. Because risks are associated with chronic exposure, regulatory documents state that regular monitoring of serum calcium and renal function is formally carried out during long-term exposure.

Q: Can Steovit D3 be taken with antacids or heartburn medication?

A: Regulatory warnings indicate caution is advised. The Vitamin D component, when taken with certain antacids (specifically those containing magnesium), may pose a risk of elevated magnesium levels. Additionally, calcium-containing products may interfere with the absorption of aluminum-containing antacids and may necessitate a time separation based on the specific formulation.

Q: Has Steovit D3 been studied in people with kidney issues?

A: Regulatory information addresses this population by noting specific risks. Patients with impaired renal function are described as being more susceptible to hypercalcaemia (high blood calcium) and toxic effects. The official documents state that use is not recommended in those with severe renal impairment.

Q: Are there any known interactions between Steovit D3 and common supplements like iron or magnesium?

A: Official warnings state that co-administration with magnesium-containing products may increase the risk of hypermagnesemia, particularly in patients with reduced kidney function.

Q: How does taking Steovit D3 affect the amount of calcium I get from food?

A: The Vitamin D component (Dihydrotachysterol) functions to increase the capacity for intestinal absorption of calcium from the digestive tract into the bloodstream. Official documents note that abrupt changes to dietary calcium intake may need to be avoided.

Q: Do official documents mention any effects of Steovit D3 on heart health?

A: Official warnings advise caution when the medicine is used in patients who are taking Cardiac Glycosides (a type of heart medicine). This is because hypercalcaemia (high blood calcium) caused by Steovit D3 may potentiate the toxic effects of these heart medications.

Q: Can Steovit D3 interact with medicines for thyroid conditions?

A: Regulatory warnings indicate a potential interaction. The calcium component may decrease and/or delay the oral absorption of certain thyroid hormones, such as levothyroxine. To manage this potential interference, a time separation between taking Steovit D3 and the thyroid hormone may be applied.

Q: What type of research evidence is typically available for a combined product like Steovit D3?

A: The evidence supporting the general use of this combination is typically derived from meta-analyses of Randomized Controlled Trials (RCTs). This research explores supplementation as an adjunct to other osteoporosis treatments or for addressing deficiencies in the elderly.

Q: What are the general rules regarding driving or operating machinery while using Steovit D3?

A: Official regulatory documents do not typically include a specific warning regarding the ability to drive or operate machinery, which suggests that no negative effects on these activities are known or expected from the product itself.

Q: How is the dose of Steovit D3 usually described in official documents?

A: Doses are commonly described in two ways on official documentation. They are presented in terms of the total weight of the calcium salt (e.g., Calcium carbonate 1250 mg) and the equivalent amount of elemental calcium (e.g., 500 mg).

Q: Is it common for people taking Steovit D3 to also take other vitamin supplements?

A: Official safety warnings note that caution is required regarding co-administration. Co-administration with other high-dose calcium supplements or other Vitamin D Analogs is officially prohibited due to the risk of an additive effect leading to hypercalcaemia (abnormally high calcium levels in the blood).

Q: What are common patient goals described in research using Steovit D3?

A: Research aims are implied by the measured outcomes. These commonly include supporting the maintenance of Bone Mineral Density (BMD) and the reduction in the risk of total and hip fractures, particularly in older adults with demonstrated deficiency.

Q: Are there certain drinks, like milk or juice, that should not be taken near the time of taking Steovit D3?

A: The official label restricts ingestion within two hours of consuming foods high in oxalic or phytic acid (found in certain leafy greens and cereals). Warnings also exist concerning the ingestion of grapefruit or grapefruit juice due to potential effects on the vitamin D analog component.

Q: What is the general reason for stopping Steovit D3 use?

A: A primary reason for stopping treatment is the development of a contraindication (a condition that makes the medicine unsafe to use). This includes the onset of hypercalcaemia (high blood calcium) or the onset of severe renal impairment.

Storage and Disposal Requirements for Steovit D3

The storage and disposal instructions for Steovit D3 are defined by regulatory documents to maintain product quality and ensure safety.

Official Storage Conditions

Requirement	Constraint
Temperature	Store below 30 C (Do not freeze).
Protection	Protect from light and moisture
Packaging	Keep the medicine in its original container and keep it tightly closed.
Safety	Keep Steovit D3 out of the sight and reach of children.
Stability	Do not use the medicine after the stated expiration date ( EXP).

---

Official Disposal Instructions

Any unused or expired Steovit D3 product must be handled in accordance with local regulations for pharmaceutical waste. Medicines must not be thrown away via household waste or wastewater. Consult a pharmacist for proper disposal methods.